US20070178092A1 - Humanized anti-CD3 specific antibodies - Google Patents

Humanized anti-CD3 specific antibodies Download PDF

Info

Publication number
US20070178092A1
US20070178092A1 US11/636,655 US63665506A US2007178092A1 US 20070178092 A1 US20070178092 A1 US 20070178092A1 US 63665506 A US63665506 A US 63665506A US 2007178092 A1 US2007178092 A1 US 2007178092A1
Authority
US
United States
Prior art keywords
antibody
ser
antibodies
gly
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/636,655
Inventor
Sarah Bolt
Michael Clark
Scott Gorman
Edward Routledge
Herman Waldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Priority to US11/636,655 priority Critical patent/US20070178092A1/en
Publication of US20070178092A1 publication Critical patent/US20070178092A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Description

  • This invention relates to novel antibodies, in particular to antibodies directed against the CD3 antigen complex.
  • Antibodies, or immunoglobulins, comprise two heavy chains linked together by disulphide bonds and two light chains, each light chain being linked to a respective heavy chain by disulphide bonds in a “Y” shaped configuration. The two “arms” of the antibody are responsible for antigen binding, and include regions where the polypeptide structure varies, these “arms” being termed Fab′ fragments (fragment—antigen—binding) or F(ab′)2 which represents two Fab′ arms linked together by disulphide bonds. The “tail” or central axis of the antibody contains a fixed or constant sequence of peptides and is termed the Fc fragment (fragment—crystalline). The production of monoclonal antibodies was first disclosed by Kohler and Milstein (Kohler & Milstein, Nature, 256, 495-497 (1975)). Such monoclonal antibodies have found widespread use as diagnostic agents and also in therapy.
  • Each heavy chain has at one end a variable domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end, the light chain variable domain being aligned with the variable domain of the heavy chain and the light chain constant domain being aligned with the first constant domain of the heavy chain (CH1). The constant domains in the light and heavy chains are not involved directly in binding the antibody to antigen. The light chain constant domain and the CH1 domain of the heavy chain account for 50% of each Fab′ fragment.
  • The variable domains of each pair of light and heavy chains form the antigen binding site. The domains on the light and heavy chains have the same general structure and each domain comprises four framework regions, whose sequences are relatively conserved, connected by three complementarity determining regions (CDRs) (Kabat et al, Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1987)). The four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs are held in close proximity by the framework regions and, with the CDRs from the other domain, contribute to the formation of the antigen binding site.
  • The human CD3 antigen consists of a minimum of four invariant polypeptide chains, which are non-covalently associated with the T-cell receptors on the surface of T-cells, and is generally now referred to as the CD3 antigen complex. It is intimately involved in the process of T-cell activation in response to antigen recognition by the T-cell receptors.
  • All CD3 monoclonal antibodies can be used to sensitise T-cells to secondary proliferative stimuli such as IL1 (interleukin 1) and IL2 (interleukin 2). In addition, certain CD3 monoclonal antibodies are themselves mitogenic for T-cells. This property is isotype dependent and results from the interaction of the CD3 antibody Fc domain with Fc receptors on the surface of accessory cells.
  • Rodent CD3 antibodies have been used to influence immunological status by suppressing, enhancing or re-directing T-cell responses to antigens. They therefore have considerable therapeutic potential in the human for use as an immunosuppressive agent, for example for the treatment of rejection episodes following the transplantation of renal, hepatic and cardiac allografts. However their value is compromised by two main factors. The first is the antiglobulin response evoked due to the xenogeneic nature of the antibody. The second is the “first dose” syndrome experienced by patients following the initial administration of the antibody. The symptoms, which range in severity from fever and chills to pulmonary edema, and which in rare cases can cause death, are caused by the elevated levels of circulating cytokines associated with CD3-antibody induced T-cell activation. This phenomenon requires the cross-linking of the CD3 antigen on the surface of T-cells to accessory cells through Fc receptors; such proliferation does not occur with F(ab′)2 fragments of CD3 antibodies.
  • The first problem can be addressed by re-shaping or “humanising” the variable region genes of antibodies and expressing them in association with relevant human constant domain genes. This reduces the non-human content of the monoclonal antibody to such a low level that an antiglobulin response is unlikely. Such a reshaped antibody with a binding affinity for the CD3 antigen complex is described in UK Patent Application No. 9121126.8 (published as GB 2249310A) and its equivalents (European Patent Application No. 91917169.4, Japanese Patent Application No. 516117/91 and U.S. patent application Ser. No. 07/862,543).
  • There remains however the problem of the first dose response when these antibodies are used in therapy. Aglycosylation of antibodies has been described to reduce their ability to bind to Fc receptors in vitro in some cases. However, it is not predictable that this will be true of all antibodies, particularly in vivo, and aglycosylation may result in the introduction into the antibody of novel and unpredictable properties including novel Fc binding characteristics causing other undesirable effects. It is also possible that other undesirable properties not associated with Fc binding may be introduced to the antibody.
  • Moreover, it is of course of vital importance that aglycosylation is not accompanied by the loss of certain desirable features of Fc binding in addition to the loss of the undesirable features such as those attributable to the first dose response.
  • It has now been found, however, that it is possible to produce aglycosylated CD3 antibodies of the IgG subclass which surprisingly retain their antigen binding specificity and immunosuppressive properties and yet do not induce T cell mitogenesis in vitro and induce a reduced level of cytokine release in vivo, whilst still maintaining some Fc binding ability.
  • Accordingly, the invention provides an aglycosylated IgG antibody having a binding affinity for the CD3 antigen complex.
  • The term aglycosylated is employed in its normal usage to indicate that the antibodies according to the invention are not glycosylated. Although the present invention can be applied to antibodies having a binding affinity for a non-human CD3 antigen complex, for example various other mammalian CD3 antigens for veterinary use, the primary value of the invention lies in aglycosylated antibodies having an affinity for the human CD3 antigen complex for use in the human and the following discussion is particularly directed to that context.
  • Further discussion of CD3 antigens is to be found in the report of the First International Workshop and Conference on Human Leukocyte Differentiation Antigens and description of various glycosylated antibodies directed against the CD3 antigen is also to be found in the reports of this series of Workshops and Conferences, particularly the Third and Fourth, published by Oxford University Press. Specific examples of such antibodies include those described by Van Ller et al., Euro. J. Immunol., 1987, 17, 1599-1604, Alegre et al., J. Immunol., 1991, 140, 1184, and by Smith et al., ibid, 1986, 16, 478, the last publication relating to the IgG1 antibody UCHT1 and variants thereof. However, of particular interest as the basis for aglycosylated antibodies according to the present invention are the CDRs contained in the antibodies OKT3 and YTH 12.5.14.2. The antibody OKT3 is discussed in publications such as Chatenaud et al., Transplantation, 1991, 51, 334 and the New England Journal of Medicine paper, 1985, 313, 339, and also in European Patent No. 0 018 795 and U.S. Pat. No. 4,361,539. The antibody YTH 12.5.14.2 (hereinafter referred to as YTH 12.5) is discussed in publications such as Clark et al., European J. Immunol., 1989, 19, 381-388 and reshaped YTH 12.5 antibodies are the subject of UK Patent Application No. 9121126.8 and its equivalents, this application describing in detail the CDRs present in this antibody.
  • Aglycosylated antibodies containing one or more of the CDRs described in the above application are of particular interest. Thus the antibodies of the invention preferably have at least one CDR selected from the amino acid sequences:
    • (a) Ser-Phe-Pro-Met-Ala (SEQUENCE ID NO. 1),
    • (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly (SEQUENCE ID NO. 2),
    • (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr (SEQUENCE ID NO. 3),
    • (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His (SEQUENCE ID NO. 4),
    • (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp (SEQUENCE ID NO. 5),
    • (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val (SEQUENCE ID NO. 6),
      and conservatively modified variants thereof.
  • The term “conservatively modified variants” is one well known in the art and indicates variants containing changes which are substantially without effect on antibody-antigen affinity.
  • The CDRs are situated within framework regions of the heavy chain (for (a), (b) and (c)) and light chain (for (d), (e) and (f)) variable domains. The antibody also comprises a constant domain.
  • In a preferred embodiment the aglycosylated antibody has three CDRs corresponding to the amino acid sequences (a), (b) and (c) above or conservatively modified variants thereof and/or three CDRs corresponding to amino acid sequences (d), (e) and (f) or conservatively modified variants thereof, the heavy chain CDRs (a), (b) and (c) being of most importance.
  • A preferred aglycosylated antibody with a binding affinity for the CD3 antigen thus has a heavy chain with at least one CDR and particularly three CDRs selected from the amino acid sequences:
    • (a) Ser-Phe-Pro-Met-Ala (SEQUENCE ID NO. 1),
    • (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly (SEQUENCE ID NO. 2),
    • (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr (SEQUENCE ID NO. 3),
      and conservatively modified variants thereof, and/or a light chain with at least one CDR and particularly three CDRs selected from the amino acid sequences:
    • (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His (SEQUENCE ID NO. 4),
    • (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp (SEQUENCE ID NO. 5),
    • (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val (SEQUENCE ID NO. 6),
      and conservatively modified variants thereof.
  • Where an aglycosylated antibody according to the invention contains preferred CDRs as described hereinbefore it conveniently contains both one or more of the specified heavy chain CDRs and one or more of the specified light chain CDRs. The CDRs (a), (b) and (c) are arranged in the heavy chain in the sequence: framework region 1/(a)/framework region 2/(b)/framework region 3/(c)/framework region 4 in a leader→constant domain (n-terminal to C-terminal) direction and the CDRs (d), (e) and (f) are arranged in the light chain in the sequence: framework region 1/(d)/framework region 2/(e)/framework region 3/(f)/framework region 4 in a leader→constant domain direction. It is preferred, therefore, that where all three are present the heavy chain CDRs are arranged in the sequence (a), (b), (c) in a leader→constant domain direction and the light chain CDRs are arranged in the sequence (d), (e), (f) in a leader→constant domain direction.
  • It should be appreciated however, that aglycosylated antibodies according to the invention may contain quite different CDRs from those described hereinbefore and that, even when this is not the case, it may be possible to have heavy chains and particularly light chains containing only one or two of the CDRs (a), (b) and (c) and (d), (e) and (f), respectively. However, although the presence of all six CDRs defined above is therefore not necessarily required in an aglycosylated antibody according to the present invention, all six CDRs will most usually be present in the most preferred antibodies. A particularly preferred aglycosylated antibody therefore has a heavy chain with three CDRs comprising the amino acid sequences (a), (b) and (c) or conservatively modified variants thereof and a light chain with three CDRs comprising the amino acid sequences (d), (e) and (f) or conservatively modified variants thereof in which the heavy chain CDRs are arranged in the order (a), (b), (c) in the leader constant region direction and the light chain CDRs are arranged in the order (d), (e), (f) in the leader constant region direction.
  • The CDRs may be of different origin to the variable framework region and/or to the constant region and, since the CDRs will usually be of rat or mouse origin, this is advantageous to avoid an antiglobulin response in the human, although the invention does extend to antibodies with such regions of rat or mouse origin.
  • More usually the CDRs are either of the same origin as the variable framework region but of a different origin from the constant region, for example in a part human chimaeric antibody, or, more commonly, the CDRs are of different origin from the variable framework region.
  • The preferred CDRs discussed hereinbefore are obtained from a rat CD3 antibody. Accordingly, although the variable domain framework region can take various forms, it is conveniently of or derived from those of a rodent, for example a rat or mouse, and more preferably of or derived from those of human origin. One possibility is for the antibody to have a variable domain framework region corresponding to that in the YTH12.5 hybridoma although the constant region will still preferably be of or derived from those of human origin. However the antibody of the invention is preferably in the humanised form as regards both the variable domain framework region and as discussed further hereinafter, the constant region.
  • Accordingly, the invention further comprises an aglycosylated antibody which has a binding affinity for the human CD3 antigen and in which the variable domain framework regions and/or the constant region are of or are derived from those of human origin.
  • Certain human variable domain framework sequences will be preferable for the grafting of the preferred CDR sequences, since the 3-dimensional conformation of the CDRs will be better maintained in such sequences and the antibody will retain a high level of binding affinity for the antigen. Desirable characteristics in such variable domain frameworks are the presence of key amino acids which maintain the structure of the CDR loops in order to ensure the affinity and specificity of the antibody for the CD3 antigen, the lambda type being preferred for the light chain.
  • Human variable region frameworks which are particularly suitable for use in conjunction with the above CDRs have been previously identified in UK Patent Application No. 9121126.8. The heavy chain variable (V) region frameworks are those coded for by the human VH type III gene VH26.D.J. which is from the B cell hybridoma cell line 18/2 (Genbank Code: Huminghat, Dersimonian et al., Journal of Immunology, 139, 2496-2501). The light chain variable region frameworks are those of the human VLλ type VI gene SUT (Swissprot code; LV6CSHum, Solomon et al. In Glenner et al (Eds), Amyloidosis, Plenum Press N.Y., 1986, p. 449.
  • The one or more preferred CDRs of the heavy chain of the rat anti-CD3 antibody are therefore preferably present in a human variable domain framework which has the following amino acid sequence reading in the leader→constant region direction, CDR indicating a CDR (a), (b) or (c) as defined hereinbefore, a conservatively modified variant thereof or an alternative CDR: -Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-/CDR/-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-/CDR/-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-Lys-/CDR/-Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQUENCE ID NO. 7/CDR/SEQUENCE ID NO. 8/CDR/SEQUENCE ID NO. 9/CDR/SEQUENCE ID NO. 10).
  • In an aglycosylated antibody containing all three preferred CDRs, the heavy chain variable region comprises the following sequence:—Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-Ser-Phe-Pro-Met-Ala-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-Lys-Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr-Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQUENCE ID NO. 11).
  • Similarly, the one or more preferred CDRs of the light chain of the rat CD3 antibody are therefore preferably present in a human variable domain framework which has the following amino acid sequence reading in the leader→constant region direction, CDR indicating a COR (d), (e) and (f) as defined hereinbefore, a conservatively modified variant thereof or an alternative CDR: -Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-Thr-Val-Ile-Ile-Ser-Cys-/CDR/-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-Pro-Thr-Thr-Val-Ile-Phe-/CDR/-Gly-Val-Pro-Asp-Arg-Phe-Ser-Gly-Ser-Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-Leu-Gln-Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-/CDR/-Phe-Gly-Gly-Gly-Thr-Lys-Leu-Thr-Val-Leu (SEQUENCE ID NO. 12/CDR/SEQUENCE ID NO. 13/CDR/SEQUENCE ID NO. 14/CDR/SEQUENCE ID NO. 15).
  • In an aglycosylated antibody containing all three preferred CDRs the light chain variable region comprises the following sequence:—Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-Thr-Val-Ile-Ile-Ser-Cys-Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-Pro-Thr-Thr-Val-Ile-Phe-Asp-Asp-Asp-Lys-Arg-Pro-Asp-Gly-Val-Pro-Asp-Arg-Phe-Ser-Gly-Ser-Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-Leu-Gln-Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val-Phe-Gly-Gly-Gly-Thr-Lys-Leu-Thr-Val-Leu (SEQUENCE ID NO. 16).
  • The variable domains, for example comprising one or more preferred CDRs as described above, preferably in the humanised form having human antibody-derived variable framework regions, are attached to appropriate constant domains.
  • The heavy and light chain constant regions can be based on antibodies of different types as desired subject to the antibody being an IgG antibody, but although they may be of or derived from those of rat or mouse origin they are preferably of or are derived from those of human origin. For the light chain the constant region is preferably of the lambda type and for the heavy chain it is preferably of an IgG isotype, especially IgG1, modified to effect aglycosylation as appropriate. All human constant regions of the IgG isotype are known to be glycosylated at the asparagine residue at position 297, which makes up part of the N-glycosylation motif Asparagine297-X298-Serine299 or Threonine299, where X is the residue of any amino acid except proline. The antibody of the invention may thus be aglycosylated by the replacement of Asparagine297 in such a constant region with another amino acid which cannot be glycosylated. Any other amino acid residue can potentially be used, but alanine is the most preferred. Alternatively, glycosylation at Asparagine297 can be prevented by altering one of the other residues of the motif, e.g. by replacing residue 298 by proline, or residue 299 by any amino acid other than serine or threonine. Techniques for performing this site directed mutagenesis are well known to those skilled in the art and may for example be performed using a site directed mutagenesis kit such, for example, as that commercially available from Amersham. The procedure is further exemplified hereinafter.
  • It is well recognised in the art that the replacement of one amino acid in a CDR with another amino acid having similar properties, for example the replacement of a glutamic acid residue with an aspartic acid residue, may not substantially alter the properties or structure of the peptide or protein in which the substitution or substitutions were made. Thus, the aglycosylated antibodies of the present invention include those antibodies containing the preferred CDRs but with a specified amino acid sequence in which such a substitution or substitutions have occurred without substantially altering the binding affinity and specificity of the CDRs. Alternatively, deletions may be made in the amino acid residue sequence of the CDRs or the sequences may be extended at one or both of the N- and C-termini whilst still retaining activity.
  • Preferred aglycosylated antibodies according to the present invention are such that the affinity constant for the antigen is 105 mole−1 or more, for example up to 1012 mole−1. Ligands of different affinities may be suitable for different uses so that, for example, an affinity of 106, 107 or 108 mole−1 or more may be appropriate in some cases. However antibodies with an affinity in the range of 106 to 108 mole−1 will often be suitable. Conveniently the antibodies also do not exhibit any substantial binding affinity for other antigens. Binding affinities of the antibody and antibody specificity may be tested by assay procedures such as those described in the Examples section hereinafter, (Effector Cell Retargetting Assay), or by techniques such as ELISA and other immunoassays.
  • Antibodies according to the invention are aglycosylated IgG CD3 antibodies having a “Y” shaped configuration which may have two identical light and two identical heavy chains and are thus bivalent with each antigen binding site having an affinity for the CD3 antigen. Alternatively, the invention is also applicable to antibodies in which only one of the arms of the antibody has a binding affinity for the CD3 antigen. Such antibodies may take various forms. Thus the other arm of the antibody may have a binding affinity for an antigen other than CD3 so that the antibody is a bispecific antibody, for example as described in U.S. Pat. No. 4,474,893 and European Patent Applications Nos. 87907123.1 and 87907124.9. Alternatively, the antibody may have only one arm which exhibits a binding affinity, such an antibody being termed “monovalent”.
  • Monovalent antibodies (or antibody fragments) may be prepared in a number of ways. Glennie and Stevenson (Nature, 295, 712-713, (1982)) describe a method of preparing monovalent antibodies by enzymic digestion. Stevenson et al. describe a second approach to monovalent antibody preparation in which enzymatically produced Fab′ and Fc fragments are chemically cross-linked (Anticancer Drug Design, 3, 219-230 (1989)). In these methods the resulting monovalent antibodies have lost one of their Fab′ arms. A third method of preparing monovalent antibodies is described in European Patent No. 131424. In this approach the “Y” shape of the antibody is maintained, but only one of the two Fab′ domains will bind to the antigen. This is achieved by introducing into the hybridoma a gene coding for an irrelevant light chain which will combine with the heavy chain of the antibody to produce a mixture of products in which the monovalent antibody is the one of interest.
  • More preferably, however, the monovalent aglycosylated CD3 antibodies of the invention are prepared by the following method. This involves the introduction into a suitable expression system, for example a cell system as described hereinafter, together with genes coding for the heavy and light chains, of a gene coding for a truncated heavy chain in which the variable region domain and first constant region domain of the heavy chain are absent, the gene lacking the exon for each of these domains. This results in the production by the cell system of a mixture of (a) antibodies which are complete bivalent antibodies, (b) antibody fragments consisting only of two truncated heavy chains (i.e. an Fc fragment) and (c) fragments of antibody which are monovalent for the CD3 antigen, consisting of a truncated heavy chain and a light chain in association with the normal heavy chain. Such an antibody fragment (c) is monovalent since it has any only one Fab′ arm. Production of a monovalent antibody in the form of such a fragment by this method is preferred for a number of reasons. Thus, the resulting antibody fragment is easy to purify from a mixture of antibodies produced by the cell system since, for example, it may be separable simply on the basis of its molecular weight. This is not possible in the method of European Patent No. 131424 where the monovalent antibody produced has similar characteristics to a bivalent antibody in its size and outward appearance. Additionally, the production of a monovalent antibody fragment by the new method uses conditions which can more easily be controlled and is thus not as haphazard as an enzyme digestion/chemical coupling procedure which requires the separation of a complex reaction product, with the additional advantage that the cell line used will continue to produce monovalent antibody fragments, without the need for continuous synthesis procedures as required in the enzyme digestion/chemical coupling procedure.
  • It is believed that aglycosylated antibodies according to the invention do not occur in nature and these aglycosylated antibodies may in general be produced synthetically in a number of ways. Most conveniently, however, appropriate gene constructs for the constant and variable regions of the heavy and light chains which are present in the antibody are separately obtained and then inserted in a suitable expression system.
  • Genes encoding the variable domains of a ligand of the desired structure may be produced and conveniently attached to genes encoding the constant domains of an antibody which have undergone site directed mutagenesis. These constant genes may be obtained from hybridoma cDNA or from the chromosomal DNA and have undergone mutagenesis (site directed) to produce the aglycosylated constant regions. Genes encoding the variable regions may also be derived by gene synthesis techniques used in the identification of the CDRs contained herein. Suitable cloning vehicles for the DNA may be of various types.
  • Expression of these genes through culture of a cell system to produce a functional CD3 ligand is most conveniently effected by transforming a suitable prokaryotic or particularly eukaryotic cell system, particularly an immortalised mammalian cell line such as a myeloma cell line, for example the YB2/3.01/Ag20 (hereinafter referred to as Y0) rat myeloma cell, or Chinese hamster ovary cells (although the use of plant cells is also of interest), with expression vectors which include DNA coding for the various antibody regions, and then culturing the transformed cell system to produce the desired antibody. Such general techniques of use for the manufacture of ligands according to the present invention are well known in the very considerable art of genetic engineering and are described in publications such as “Molecular Cloning” by Sambrook, Fritsch and Maniatis, Cold Spring Harbour Laboratory Press, 1989 (2nd edition). The techniques are further illustrated by the Examples contained herein.
  • The present invention thus includes a process for the preparation of an aglycosylated IgG antibody having a binding affinity for the CD3 antigen which comprises culturing cells capable of expressing the antibody in order to effect expression thereof. The invention also includes a cell line which expresses an aglycosylated antibody according to the invention.
  • Preferred among such cell lines are those which comprise DNA sequences encoding the preferred CDRs described hereinbefore. A group of nucleotide sequences coding for the CDRs (a) to (f) described hereinbefore is as indicated under (a) to (f) below, respectively, but it will be appreciated that the degeneracy of the genetic code permits variations to be made in these sequences whilst still encoding for the CDRs' amino acid sequences.
  • (a) AGCTTTCCAA TGGCC (SEQUENCE ID NO. 17)
  • (b) ACCATTAGTA CTAGTGGTGG TAGAACTTAC TATCGAGACT CCGTGAAGGG C (SEQUENCE ID NO. 18)
  • (c) TTTCGGCAGT ACAGTGGTGG CTTTGATTAC (SEQUENCE ID NO. 19)
  • (d) ACACTCAGCT CTGGTAACAT AGAAAACAAC TATGTGCAC (SEQUENCE ID NO. 20)
  • (e) GATGATGATA AGAGACCGGA T (SEQUENCE ID NO. 21)
  • (f) CATTCTTATG TTAGTAGTTT TAATGTT (SEQUENCE ID NO. 22)
  • Such cell lines will particularly contain larger DNA sequences which comprise (1) DNA expressing human heavy chain variable framework regions and one or more of (a), (b) and (c), and (2) DNA expressing human light chain variable framework regions and one or more of (d), (e) and (f). A specific example of such DNA is that sequence (1) indicated below which codes for the CDRs (a), (b) and (c) arranged in the heavy chain framework coded for by the human VH type III gene VH26.D.J. as discussed hereinbefore and that sequence (2) indicated below which codes for the CDRs (d), (e) and (f) arranged in the light chain framework coded for by the human VLλ type VI gene SUT. The CDR sequences (a), (b), (c), (d), (e) and (f) have been underlined.
    • (1) GAGGTCCAAC TGCTGGAGTC TGGGGGCGGT TTAGTGCAGC CTGGAGGGTC CCTGAGACTC TCCTGTGCAG CCTCAGGATT CACTTTCAGT AGCTTTCCAA TGGCCTGGGT CCGCCAGGCT CCAGGGAAGG GTCTGGAGTG GGTCTCAACC ATTAGTACTA GTGGTGGTAG AACTTACTAT CGAGACTCCG TGAAGGGCCG ATTCACTATC TCCAGAGATA ATAGCAAAAA TACCCTATAC CTGCAAATGA ATAGTCTGAG GGCTGAGGAC ACGGCCGTCT ATTACTGTGC AAAATTTCGG CAGTACAGTG GTGGCTTTGA TTACTGGGGC CAAGGGACCC TGGTCACCGl CTCCTCA (SEQUENCE ID NO. 23)
    • (2) GACTTCATGC TGACTCAGCC CCACTCTGTG TCTGAGTCTC CCGGAAAGAC AGTCATTATT TCTTGCACAC TCAGCTCTGG TAACATAGAA AACAACTATG TGCACTGGTA CCAGCAAAGG CCGGGAAGAG CTCCCACCAC TGTGATTTTC GATGATGATA AGAGACCGGA TGGTGTCCCT GACAGGTTCT CTGGCTCCAT TGACAGGTCT TCCAACTCAG CCTCCCTGAC AATCAGTGGT CTGCAAACTG AAGATGAAGC TGACTACTAC TGTCATTCTT ATGTTAGTAG TTTTAATGTT TTCGGCGGTG GAACAAAGCT CACTGTCCTT (SEQUENCE ID NO. 24)
  • The cell lines will of course also particularly contain DNA sequences expressing the heavy and light chain constant regions.
  • The humanised aglycosylated antibodies in accordance with the invention have therapeutic value. In particular, such aglycosylated antibodies, especially a humanised aglycosylated antibody with a specificity for the human CD3 antigen, has valuable applications in immunosuppression, particularly in the control of graft rejection, where it is especially desirable that immunosuppression is temporary rather than total, and thus that T-cells are not completely destroyed, but instead rendered non-functional by antibody blockade of the CD3 antigen-TCR complex. In addition, the aglycosylated CD3 antibodies may have potential in other areas such as in the treatment of cancer, specifically in the construction of bispecific antibodies (for effector cell retargetting) or antibody-toxin conjugates, where the efficacy of the therapeutic agent would be compromised by Fc-mediated killing of the effector cells or non-specific killing of Fc receptor bearing cells respectively.
  • In a further aspect, the invention thus includes a method of treating patients with cancer, particularly a lymphoma, or for immunosuppression purposes, for instance in a case where graft rejection may occur, comprising administering a therapeutically effective amount of an aglycosylated antibody in accordance with the invention.
  • Aglycosylated antibodies in accordance with the invention may be formulated for administration to patients by administering the said antibody together with a physiologically acceptable diluent or carrier. The antibodies are preferably administered in an injectable form together with such a diluent or carrier which is sterile and pyrogen free. By way of guidance it may be stated that a suitable dose of antibody is about 1-10 mg injected daily over a time period of, for example 10 days, although due to the elimination of the first dose response it will be possible if desired to administer higher amounts of the antibody, for example even up to 100 mg daily, depending on the individual patient's needs. Veterinary use is on a similar g/kg dosage basis.
  • The invention is illustrated by the following Examples which are illustrated by the drawings listed below:
  • FIGS. 1-8: These figures show the results of proliferation assays of peripheral blood lymphocytes to CD3 antibodies. Four different healthy volunteers were used. The humanised anti-lymphocyte antibody CDw52 was included as a negative control.
  • FIGS. 9-12: These figures show the comparison of aglycosylated CD3 antibody and glycosylated CD3 antibody in a mixed lymphocyte reaction. Aglycosylated antibody specific for the mouse CD8 antigen was included as a negative control.
  • FIGS. 13 & 14: These figures show the results of an Effector Cell Retargetting Assay comparing glycosylated and aglycosylated IgG-type CD3 antibodies. The CDw52 antibody was used as a negative control.
    • EXAMPLES Example 1 Preparation of an Aglycosylated Antibody Specific for the Human CD3 Antigen Containing CDRs from the YTH 12.5 Rat Antibody in Human Variable Framework Regions
  • The cloning and re-shaping of the V-region gene of the rat antibody YTH 12.5 specific for the human CD3 antigen was performed as described in Routledge et al., 1991, Eur. J. Immunol., 21, 2717 and in UK Patent Application No. 9121126.8 and its equivalents. YTH 12.5 is a rat hybridoma cell line secreting an IgG2b monoclonal antibody specific for the CD3 antigen complex.
  • Briefly, the methodology was based on that of Orlandi et al., 1989, PNAS USA, 86, 3833, using the polymerase chain reaction (PCR). The VH gene (heavy chain variable region gene) was cloned using oligonucleotide primers VH1FOR and VH1BACK. The PCR products were ligated into the vector M13-VHPCR1 in which site directed mutagenesis was performed using 6 oligonucleotide primers. The VL gene (light chain variable region gene) was cloned using primers designed based on the published VLλ sequences. The gene was cloned into the vector M13-VKPCR, together with the human lambda light chain constant region. In this vector mutagenesis of the VL framework was performed using 5 oligonucleotides. The humanised VL gene was then inserted into the expression vector pHβApr-1.
  • A vector was generated (p316) in which the reshaped CD3 VH gene could be expressed in conjunction with different immunoglobulin H chain constant region genes, this vector being based on the pHβApr-gpt vector (Gunning et al., 1987, P.N.A.S. USA, 85, 7719-7723). A 1.65 Kb fragment of DNA carrying the dihydrofolate reductase (dhft) gene and SV 40 expression signals (Page & Sydenham, 1991, Biotechnology, 9, 64) was inserted into the unique EcoRI site of pHβApr-gpt. A 700 bp HindIII-BamHI DNA fragment encoding the reshaped CD3-VH gene was then cloned into the vector's multiple cloning site, downstream and under the control of the β actin promoter. The desired H chain constant region gene (in genomic configuration) could then be inserted into the unique BamH1 restriction enzyme site downstream of the CD3-VH gene.
  • The aglycosyl human IgG1 constant region was derived from the wild type Glm (1,17) gene described by Takahashi et al., (1982, Cell, 29, 671-679) as follows. The gene was cloned into the vector M13 tg131 where site-directed mutagenesis was performed (Amersham International PLC) to mutate the amino acid residue at position 297 from an asparagine to an alanine residue.
  • Oligosaccharide at Asn-297 is a characteristic feature of all normal human IgG antibodies (Kabat et al., 1987, Sequence of Proteins of Immunological Interest, US Department of Health Human Services Publication), each of the two heavy chains in the IgG molecules having a single branched chain carbohydrate group which is linked to the amide group of the asparagine residue (Rademacher and Dwek, 1984, Prog. Immunol., 5, 95-112). Substitution of asparagine with alanine prevents the glycosylation of the antibody.
  • The 2.3 Kb aglycosyl IgG1 constant region was excised from M13 by double digestion using BamHI and BgIII and ligated into the BamHI site of vector p316 to produce clone p323.
  • Subconfluent monolayers of dhfr− Chinese Hamster Ovary cells were co-transfected with the vector p323 containing the heavy chain gene and a second vector p274 containing the re-shaped human γ light chain (Routledge et al., 1991, Eur. J. Immunol., 21, 2717-2725). Prior to tranfection both plasmid DNAs were linearised using the restriction endonuclease PvuI. Transfection was carried out using the DOTMA reagent (Boehringer, Germany) following the manufacturer's recommendations.
  • Heavy and light chain transfectants were selected for in xanthine/hypoxanthine free IMDM containing 5% (v/v) dialysed foetal calf serum.
  • The production of the analogous wild type human IgG1-CD3 heavy chain vector p278 has been described elsewhere (Routledge et al., 1991, Eur. J. Immunol., 21, 2717-2725). H-chain expression vectors carrying the non-mutant human IgG2 (Flanagan & Rabbitts, 1982, Nature 300, 709-713), IgG3 (Huck et al., 1986, Nuc. Acid. Res., 14, 1779-1789), IgG4 (Flanagan & Rabbitts, 1982, Nature 300, 709-713), Epsilon (Flanagan & Rabbitts, 1982, EMBO. Journal 1, 655-660) and Alpha-2 (Flanagan & Rabbitts, 1982, Nature 300, 709-713) constant region genes (vectors p317, p318, p320, p321 and p325, respectively) were derived from the vector p316. Introduction of these vectors, in conjunction with the light chain vector p274, into dhfr− CH0 cells as described earlier, produced cell lines secreting CD3 antibody of the γ1, γ2, γ3, γ4, ε and α-2 isotype respectively. Cells expressing CD3 antibodies were subjected to two rounds of cloning in soft agar, and then expanded into roller bottle cultures. The immunoglobulin from approximately 4 litres of tissue culture supernatant from each cell line was concentrated by ammonium sulphate precipitation, dialysed extensively against PBS and then quantified as follows:
  • As the antibody was not pure, a competition assay was designed to specifically quantitate the concentration of antibody with CD3 antigen binding capacity. Human T-cell blasts were incubated with FITC labelled UCHT-1, an antibody which binds to the same epitope of the CD3 antigen as the chimaeric panel. The concentration of FITC reagent used had previously been determined to be half saturating. Unlabelled YTH 12.5 (HPLC purified) was titrated from a known starting concentration and added to wells containing T-cells and UCHT-1 FITC. The unlabelled antibody serves as a competitor for the antigen binding site. This is detected as decrease in the mean fluorescence seen when the cells are studied using FACS analysis. Thus, titration of the chimaeric antibodies from unknown starting concentrations yields a series of sigmoidal curves when mean fluorescence is plotted against antibody dilution. These can be directly compared with the standard YTH 12.5 curve.
    • Example 2 Proliferation Assays
  • The capacity of a CD3 antibody to support T-cell proliferation in solution is related to the interaction of the Fc region of the antibody with Fc receptors on accessory cells.
  • The aglycosylated chimaeric CD3 antibody prepared as described in Example 1 was compared with a panel of other chimaeric antibodies which shared the same variable region architecture but different H chain constant regions (see Example 1) for the ability to induce proliferation of human peripheral blood lymphocytes. Lymphocytes isolated from healthy donors' blood were separated on a lymphopaque gradient, washed and resuspended in IMDM containing 5% (v/v) heat-inactivated human AB serum and plated at 5×104 to 1×105 cells per well in plates containing CD3 antibodies in solution. After 3 days in culture the cells were pulse labelled with tritiated thymidine and harvested 6 hours later and the level of cellular 3H incorporation was determined by scintillation counting. The proliferation response to titrated antibody was studied in four blood donors. For a fifth donor the proliferation response was studied only at 1 μg. The results are shown in FIGS. 1 to 8.
  • For the donors studied, all ‘wild type’ antibodies led to T-cell proliferation. However the mutant, aglycosylated IgG1 isotype was never mitogenic implicating an important role for the carbohydrate side chains.
  • In a separate experiment, the ability of a panel of CD3 monoclonal antibodies in solution to stimulate T-cell mitogenesis was studied using lymphocytes isolated from the blood of 10 donors from a variety of ethnic backgrounds. All of the naturally occurring isotypes caused proliferation in the presence of 5% human AB serum, although there were T-cell donor dependent variations in the extent of the responses caused by the antibodies. In general, the γ1 and ε monoclonal antibodies were the most mitogenic, activating cells at the lowest concentration, and the γ3 and γ2 were the least active. The aglycosyl derivative of the γ1 monoclonal antibody was the only CD3 antibody which consistently failed to induce T-cell proliferation in any of the donors tested, giving responses equivalent to those of the non-activating control monoclonal antibody Campath-1H. In order to exclude endotoxin contamination as the cause of the proliferation seen with the α2 and ε preparations, it was confirmed that proliferation could be blocked by the addition of an excess of the aglycosyl CD3 mAb thus implicating the CD3 antigen in the activation process.
  • The total lack of proliferative response seen with the aglycosyl γ1 CD3 monoclonal antibody was surprising, given its position in the ECR activity hierarchy (see Example 5 below). The reason for this inactivity is probably due to its reduced affinity for FcRs rather than because aglycosylation has abolished the ability to trigger some post-binding event required for proliferation, e.g. by destroying a secondary recognition site on the monoclonal antibody. This is supported by the observation that the aglycosyl γ1 mAb could stimulate proliferation to a considerable degree if the assay was performed in IgG-free medium. There is probably a minimum thereshold level for the number of contacts or strength of interaction between T-cell and accessory cell which must be exceeded before proliferation can be initiated, and this cannot be achieved by the aglycosyl γ1 mAb in the presence of significant levels of competing immunoglobulin.
    • Example 3 The effect of Chimaeric CD3 Antibodies in Mixed Lymphocyte Reactions
  • A series of experiments was conducted to test whether the aglycosylated antibody IgG1Ag of Example 1 had the capacity to block T-cell proliferation in a mixed lymphocyte reaction (MLR) and the results of 2 experiments are shown in FIGS. 9 to 12.
  • Peripheral blood lymphocytes were isolated from two blood donors. The stimulator cell population was caesium irradiated. The responder population was incubated with titrated antibody for 30 minutes before the irradiated stimulator cells were added (FIGS. 9, 10 and 11). Control wells of responder cells were also incubated with irradiated responder cells at each antibody condition, to determine the specific effect of the antibody on the responder cells (FIGS. 9, 10 and 12).
  • After 5 days incubation the wells were pulse labelled with tritiated thymidine and harvested 6 hours later.
  • The aglycosylated antibody does block the mixed lymphocyte reaction; as the antibody is titrated out the blockade effect is less and the proliferation increases. The ‘wild type’ IgG1 actually has a mitogenic effect on the T-cells and so any blockade of the MLR is not seen through this response.
  • An ‘irrelevant’ aglycosylated antibody specific for the murine CD8 antigen was included as a negative control. This antibody has as expected no effect on the MLR.
    • Example 4 In vivo Effect of IqG1 Antibodies
  • In vivo experiments were performed with chimaeric anti-human CD3 antibodies in mice which were transgenic for the human CD3 epsilon subunit including the aglycosylated antibody of Example 1 (IgG1Ag). The ability of some of the chimaeric CD3 antibodies to cause the release of TNF factor following a single injection was compared.
  • In this set of experiments serum was collected from the mice before injection and then at 90 minutes and 4 hours following intravenous injection with 10 μg of relevant CD3 antibody. Groups consisted of 5 mice and the serum collected from each group was pooled. Analysis of the level of TNF in the serum was performed in the laboratory of Professor Jean-Francois Bach, using a bioassay which measured the cytotoxic effect of sera on the L929 mouse fibroblast cells as a result of the presence of TNF.
  • The results are shown in Table 1 below:
    TABLE 1
    TNF detected in serum of hCD3 mice following injection
    with chimaeric CD3 antibodies
    Prebleed 90 minute 4 hour
    Sample TNF level TNF level TNF level
    Saline
    0 units/ml  0 units/ml 0 units/ml
    IgG1
    0 units/ml >400 units/ml  0 units/ml
    IgG2
    0 units/ml >400 units/ml  0 units/ml
    IgG1Ag
    0 units/ml 50 units/ml 0 units/ml
    IgE
    0 units/ml 50 units/ml 25 units/ml 
    YTH 12.5 0 units/ml 50 units/ml 0 units/ml
  • A significant difference is seen between the level of TNF associated with injection of the two forms of human IgG1. The aglycosylated form is associated with at least an eight-fold less release of TNF than the wild type IgG1, or with the IgG2 antibody.
  • The results of Examples 2-4 show that the aglycosylated CD3 antibody was not mitogenic to T-cells in solution indicating that the antibody had a reduced capacity to interact with Fc receptors on accessory cells. The antibody retained the immunosuppressive properties that are characteristic of CD3 antibodies. In vivo the aglycosylated antibody led to a significantly lower release of tumour necrosis factor in human CD3 transgenic mice than the parental IgG1 antibody. Thus this agent may be an ‘improved’ CD3 antibody for the purposes of immunosuppression if the decreased TNF release seen in mice is mirrored in humans.
    • Example 5 Effector Cell Retargetting Assays for the Detection of CD3 Antibodies with the Ability to Direct T-Cell Killing
  • This was performed as described elsewhere (Gilliland et al., 1988, PNAS USA, 85, 4419) and measures the ability of a CD3 monoclonal antibody to cross-link activated T-cells to FcγR bearing target cells and thus to mediate target cell lysis. Briefly U937 human monocytic human cells which express the Fcγ receptors I, II and III were labelled with 5 Cr sodium chromate and resuspended to 2×105 cells per ml. These cells were used as targets. Human T cell blasts, generated from human peripheral blood lymphocytes by activation with mitogenic CD3 antibody followed by culture in medium containing IL-2, were used as the effector cells. They were washed and resuspended at a concentration of 2×105 cells ml−1 prior to use in the assay. 100 μl volumes of the purified chimaeric antibody preparations were diluted in 3-fold steps in the wells of a microtitre plate. 50 μl each of the effector and target cells were then added to each well and the mixture was incubated at 37° C. for at least 4 hours. After this time 100 μl of supernatant was removed and assayed for released 51Cr. Each antibody dilution was tested in duplicate.
  • The U937 monocytic cell line expresses human Fc receptors and can be lysed by activated human T-cell blasts in the presence of CD3 monoclonal antibodies capable of cross-linking the two cell types. The results (FIGS. 13 and 14) show that when aglycosylated, the human IgG1 antibody of Example 1 is still able to cross-link 1-cells to the U937 cells, albeit at a reduced level, and thus redirect T-cell cytotoxicity. This was a surprising finding since, given the published data, the effective killing mediated by aglycosyl γ1 monoclonal antibody was unexpected.
  • There existed the possibility that removal of the carbohydrate had made this monoclonal antibody especially sticky, and so able to bind to U937 cells without interacting with FcγRs. However, it was subsequently demonstrated (results not shown) that the ability of the aglycosyl γ1 monoclonal antibody to mediate the destruction of mouse L cell targets (a mouse cell line which expresses the human FcγRI) was dependent on the expression of a transfected human FcγRI gene, thus confirming the FcγR binding activity of this monoclonal antibody. We conclude that the ECR assay is a particularly sensitive method of detecting Fc-FcR interactions.
  • The ECR results indicate that the hierarchy of binding of the IgG chimaeric antibodies is γ2<γ3<Agγ1<γ4<γ1. If the assumption is made that the mitogenic activity of an antibody is predicted by its Fc receptor binding ability, then one would expect the above hierarchy to be displayed in the T cell proliferation assays. However, this was not the case; the order of activities in T cell proliferation experiments (1 to 3) was Agγ<γ2<γ4<γ3<γ1. This demonstrates that the mitogenicity of an antibody cannot be predicted in a straightforward fashion from the results of assays which measure Fc-Fc receptor interactions. This view is supported by the behaviour of the epsilon chimaeric antibody which performed poorly in the ECR assay and yet consistently had the highest mitogenic activity. This suggests that antibodies can activate T cells by binding to something other than Fcγ receptors (as displayed on U937 cells) on accessory cells, i.e. an inability to bind to Fcγ receptors is no guarantee that an antibody will not be mitogenic.

Claims (2)

1-27. (canceled)
28. A method of treating a patient requiring immunosuppression which comprises administering to said patient a therapeutically effective amount of a ligand having a binding affinity for the CD3 antigen complex.
US11/636,655 1992-03-24 2006-12-11 Humanized anti-CD3 specific antibodies Abandoned US20070178092A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/636,655 US20070178092A1 (en) 1992-03-24 2006-12-11 Humanized anti-CD3 specific antibodies

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB929206422A GB9206422D0 (en) 1992-03-24 1992-03-24 Antibody preparation
GB9206422.9 1992-03-24
US07/988,925 US5585097A (en) 1992-03-24 1992-10-21 Humanized anti-CD3 specific antibodies
PCT/GB1992/001933 WO1993019196A1 (en) 1992-03-24 1992-10-21 ANTI-CD3 AGLYCOSYLATED IgG ANTIBODY
GBPCT/GB92/01933 1992-10-21
US08/478,684 US6706265B1 (en) 1992-03-24 1995-06-07 Humanized anti-CD3 specific antibodies
US10/743,423 US20040202657A1 (en) 1992-03-24 2003-12-23 Humanized anti-CD3 specific antibodies
US11/300,278 US20060165691A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/636,655 US20070178092A1 (en) 1992-03-24 2006-12-11 Humanized anti-CD3 specific antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/300,278 Continuation US20060165691A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies

Publications (1)

Publication Number Publication Date
US20070178092A1 true US20070178092A1 (en) 2007-08-02

Family

ID=10712757

Family Applications (11)

Application Number Title Priority Date Filing Date
US07/988,925 Expired - Lifetime US5585097A (en) 1992-03-24 1992-10-21 Humanized anti-CD3 specific antibodies
US08/478,684 Expired - Fee Related US6706265B1 (en) 1992-03-24 1995-06-07 Humanized anti-CD3 specific antibodies
US10/743,423 Abandoned US20040202657A1 (en) 1992-03-24 2003-12-23 Humanized anti-CD3 specific antibodies
US11/300,396 Abandoned US20060165693A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/300,563 Abandoned US20060088526A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/300,279 Abandoned US20060165692A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/300,278 Abandoned US20060165691A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/501,894 Abandoned US20060269547A1 (en) 1992-03-24 2006-08-10 Humanized anti-CD3 specific antibodies
US11/636,655 Abandoned US20070178092A1 (en) 1992-03-24 2006-12-11 Humanized anti-CD3 specific antibodies
US11/700,150 Abandoned US20070134241A1 (en) 1992-03-24 2007-01-31 Humanized anti-CD3 specific antibodies
US11/704,940 Abandoned US20070154477A1 (en) 1992-03-24 2007-02-12 Humanized anti-CD3 specific antibodies

Family Applications Before (8)

Application Number Title Priority Date Filing Date
US07/988,925 Expired - Lifetime US5585097A (en) 1992-03-24 1992-10-21 Humanized anti-CD3 specific antibodies
US08/478,684 Expired - Fee Related US6706265B1 (en) 1992-03-24 1995-06-07 Humanized anti-CD3 specific antibodies
US10/743,423 Abandoned US20040202657A1 (en) 1992-03-24 2003-12-23 Humanized anti-CD3 specific antibodies
US11/300,396 Abandoned US20060165693A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/300,563 Abandoned US20060088526A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/300,279 Abandoned US20060165692A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/300,278 Abandoned US20060165691A1 (en) 1992-03-24 2005-12-15 Humanized anti-CD3 specific antibodies
US11/501,894 Abandoned US20060269547A1 (en) 1992-03-24 2006-08-10 Humanized anti-CD3 specific antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/700,150 Abandoned US20070134241A1 (en) 1992-03-24 2007-01-31 Humanized anti-CD3 specific antibodies
US11/704,940 Abandoned US20070154477A1 (en) 1992-03-24 2007-02-12 Humanized anti-CD3 specific antibodies

Country Status (12)

Country Link
US (11) US5585097A (en)
EP (1) EP0586617B1 (en)
JP (3) JP4065554B2 (en)
KR (1) KR100238497B1 (en)
AT (1) ATE155818T1 (en)
AU (1) AU671085B2 (en)
CA (1) CA2109815C (en)
DE (1) DE69221147T2 (en)
ES (1) ES2106195T3 (en)
GB (1) GB9206422D0 (en)
GR (1) GR3024489T3 (en)
WO (1) WO1993019196A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177896A1 (en) * 2004-06-03 2006-08-10 Bernard Mach Anti-CD3 antibodies and methods of use thereof
US20070065437A1 (en) * 2005-09-12 2007-03-22 Greg Elson Anti-CD3 antibody formulations
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP4503706B2 (en) * 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド Humanized antibodies with modified glycosylation
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
WO2002061090A2 (en) * 2000-12-14 2002-08-08 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US6720165B2 (en) * 2001-06-14 2004-04-13 Zyomix, Inc. Methods for making antibody fragments and compositions resulting therefrom
ATE382053T1 (en) * 2001-08-27 2008-01-15 Genentech Inc SYSTEM FOR ANTIBODIES EXPRESSION AND SYNTHESIS
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
ES2326964T3 (en) * 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS.
CA2483729A1 (en) * 2002-04-25 2003-11-06 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
DE602004029252D1 (en) * 2003-06-13 2010-11-04 Biogen Idec Inc AGLYCOSYL-ANTI-CD154 (CD40-LIGAND) ANTIBODIES AND THEIR USES
CN1871259A (en) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 Improved antibodies having altered effector function and methods for making the same
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
EP1682584B1 (en) 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
PT1699821E (en) 2003-12-31 2012-08-23 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154 antibodies
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
EP2937360A1 (en) * 2005-06-17 2015-10-28 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
EP2497496A3 (en) 2005-07-11 2013-02-20 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CN101258164B (en) * 2005-08-16 2013-05-01 韩美科学株式会社 A method for the mass production of immunoglobulin fc region deleted initial methionine residues
JP2009521912A (en) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CD19 antibody with reduced immunogenicity
PT1966238E (en) 2005-12-30 2012-07-31 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
WO2007145941A2 (en) 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP5597793B2 (en) * 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション ILT3-binding molecules and uses thereof
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
ES2591281T3 (en) 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies with modified isoelectric points
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
PT2691417T (en) 2011-03-29 2018-10-31 Roche Glycart Ag Antibody fc variants
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
ES2893855T3 (en) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Therapeutic agent for autoimmune diseases comprising PD-1 agonist
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HUE056217T2 (en) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9645151B2 (en) 2012-08-17 2017-05-09 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found Target peptides for immunotherapy and diagnostics
EP2892544A4 (en) 2012-09-05 2016-11-02 Univ Virginia Patent Found Target peptides for colorectal cancer therapy and diagnostics
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP2016093104A (en) * 2013-02-19 2016-05-26 国立大学法人京都大学 ANTIHUMAN CD3ε ANTIBODY OR FRAGMENT THEREOF, AND IMMUNOSUPPRESSIVE AGENT CONTAINING IT AS ACTIVE INGREDIENT
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
KR101895634B1 (en) 2013-05-31 2018-09-05 한미약품 주식회사 IgG4 Fc fragment comprising modified hinge region
HRP20220553T1 (en) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
MA47849A (en) 2014-05-28 2020-01-29 Agenus Inc ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
BR112017011166A2 (en) 2014-11-26 2018-02-27 Xencor, Inc. heterodimeric antibodies that bind to cd3 and cd38
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
MA45352A (en) 2015-08-07 2018-06-13 Univ Birmingham IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY
EA201890630A1 (en) 2015-09-01 2018-10-31 Эйдженус Инк. ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
CN108883173B (en) 2015-12-02 2022-09-06 阿吉纳斯公司 Antibodies and methods of use thereof
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
MX2018014387A (en) 2016-05-27 2019-03-14 Agenus Inc Anti-tim-3 antibodies and methods of use thereof.
MX2018015592A (en) 2016-06-14 2019-04-24 Xencor Inc Bispecific checkpoint inhibitor antibodies.
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
TW202246349A (en) 2016-10-11 2022-12-01 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
AU2017342559B2 (en) 2016-10-14 2022-03-24 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
MX2019006340A (en) 2016-12-07 2019-11-07 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof.
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
BR112019017241A2 (en) 2017-04-13 2020-04-14 Agenus Inc anti-cd137 antibodies and methods of using them
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
AU2018288803A1 (en) 2017-06-20 2020-02-06 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
JP2020529832A (en) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド Targeted heterodimer Fc fusion protein containing IL-15 / IL-15Rα and antigen binding domain
EP4327819A2 (en) 2017-06-30 2024-02-28 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
CR20200099A (en) 2017-08-03 2020-07-24 Amgen Inc Interleukin-21 muteins and methods of treatment
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
KR20200104364A (en) 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 CD3-delta/epsilon heterodimer specific antibody
CR20200330A (en) 2018-01-12 2020-12-23 Amgen Inc Anti-pd-1 antibodies and methods of treatment
TWI804572B (en) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 Bispecific antibody
BR112020017925A2 (en) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. ANTIBODIES AGAINST B7-H4 AND METHODS OF USE OF THE SAME
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019231326A1 (en) 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3830122A1 (en) 2018-07-31 2021-06-09 Amgen Research (Munich) GmbH Dosing regimen for bcma-cd3 bispecific antibodies
MA53330A (en) 2018-08-03 2021-06-09 Amgen Inc ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3
WO2020069303A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Antibodies against soluble bcma
JP2022503959A (en) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド IL-12 heterodimer FC-fusion protein
NL2021789B1 (en) 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof
CA3118397A1 (en) 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
CN116726361A (en) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 Methods and devices for treating diseases with biologic therapeutic agents
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
JPWO2020250940A1 (en) 2019-06-11 2020-12-17
JP2022537931A (en) 2019-06-14 2022-08-31 テネオバイオ， インコーポレイテッド A multispecific heavy chain antibody that binds to CD22 and CD3
US20220242962A1 (en) 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
EP3819007A1 (en) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
BR112022021690A2 (en) 2020-04-29 2022-12-20 Teneobio Inc MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
JP2023528235A (en) 2020-05-17 2023-07-04 アストラゼネカ・ユーケイ・リミテッド SARS-CoV-2 Antibodies and Methods of Selecting and Using The Same
MX2022014636A (en) 2020-05-19 2023-02-23 Amgen Inc Mageb2 binding constructs.
WO2022031978A1 (en) 2020-08-06 2022-02-10 Bioverativ Usa Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
US20220041694A1 (en) 2020-08-10 2022-02-10 Astrazeneca Uk Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
NL2026614B1 (en) 2020-10-02 2022-06-03 Academisch Ziekenhuis Leiden T cell receptors directed against bob1 and uses thereof
JP2023547662A (en) 2020-11-06 2023-11-13 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Polypeptide constructs that selectively bind to CLDN6 and CD3
WO2022096704A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
TW202233682A (en) 2020-11-10 2022-09-01 美商安進公司 Methods for administering a bcmaxcd3 binding molecule
MX2023006426A (en) 2020-12-01 2023-07-17 Aptevo Res And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies.
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4313296A1 (en) 2021-03-31 2024-02-07 Bioverativ USA Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Anti-il-9 antibodies and methods of use thereof
CA3232806A1 (en) 2021-09-30 2023-04-06 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
TW202342095A (en) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 Composition for treatment and prevention of covid-19
CA3235096A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
NL2030990B1 (en) 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
NL2031118B1 (en) 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023219510A1 (en) 2022-05-13 2023-11-16 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
NL2032130B1 (en) 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
WO2023245048A1 (en) 2022-06-15 2023-12-21 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
WO2023250507A1 (en) 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5585097A (en) * 1992-03-24 1996-12-17 British Technology Group Limited Humanized anti-CD3 specific antibodies
US5968509A (en) * 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE10199051I2 (en) * 1988-02-12 2005-05-04 Btg Int Ltd Modified antibodies.
FI105320B (en) * 1988-04-04 2000-07-31 Oncogen Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
EP0359096B1 (en) * 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991001752A1 (en) * 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP2711163B2 (en) * 1990-01-12 1998-02-10 新日本製鐵株式会社 Method for producing high corrosion resistant low alloy linepipe steel with excellent corrosion resistance
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP0559823A4 (en) * 1990-11-27 1994-05-18 Paraspectives Inc A system for imaging objects in alternative geometries
ES2206447T3 (en) * 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5968509A (en) * 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
US5585097A (en) * 1992-03-24 1996-12-17 British Technology Group Limited Humanized anti-CD3 specific antibodies
US6706265B1 (en) * 1992-03-24 2004-03-16 Btg International Limited Humanized anti-CD3 specific antibodies

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177896A1 (en) * 2004-06-03 2006-08-10 Bernard Mach Anti-CD3 antibodies and methods of use thereof
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US20100183554A1 (en) * 2004-06-03 2010-07-22 Novimmune Sa Anti-CD3 Antibodies and Methods of Use Thereof
US8551478B2 (en) 2004-06-03 2013-10-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US9850304B2 (en) 2004-06-03 2017-12-26 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US10759858B2 (en) 2004-06-03 2020-09-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US20070065437A1 (en) * 2005-09-12 2007-03-22 Greg Elson Anti-CD3 antibody formulations
US20100209437A1 (en) * 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy

Also Published As

Publication number Publication date
DE69221147D1 (en) 1997-09-04
JP4113467B2 (en) 2008-07-09
GB9206422D0 (en) 1992-05-06
CA2109815C (en) 2003-02-04
AU671085B2 (en) 1996-08-15
US6706265B1 (en) 2004-03-16
US20070134241A1 (en) 2007-06-14
EP0586617A1 (en) 1994-03-16
US20070154477A1 (en) 2007-07-05
DE69221147T2 (en) 1998-01-15
WO1993019196A1 (en) 1993-09-30
JP4065554B2 (en) 2008-03-26
ES2106195T3 (en) 1997-11-01
US20060165691A1 (en) 2006-07-27
US20040202657A1 (en) 2004-10-14
JP4113890B2 (en) 2008-07-09
US20060165693A1 (en) 2006-07-27
JP2006089501A (en) 2006-04-06
AU2766892A (en) 1993-10-21
KR100238497B1 (en) 2000-01-15
ATE155818T1 (en) 1997-08-15
US20060088526A1 (en) 2006-04-27
EP0586617B1 (en) 1997-07-23
CA2109815A1 (en) 1993-09-30
JPH07500017A (en) 1995-01-05
US5585097A (en) 1996-12-17
US20060165692A1 (en) 2006-07-27
JP2004000249A (en) 2004-01-08
GR3024489T3 (en) 1997-11-28
US20060269547A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
US5585097A (en) Humanized anti-CD3 specific antibodies
US7993641B2 (en) Methods of treatment using anti-CD3 antibodies
EP2221316A1 (en) Anti-CD19 antibody therapy for autoimmune disease
HUE035520T2 (en) Interferon alpha antibodies and their uses
AU2002226086B2 (en) Silensed anti-CD28 antibodies and use thereof
GB2376467A (en) TRX1 Antibodies

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION